Jaiswal Praveen Kumar, Goel Apul, Mittal R D
Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Indian J Med Res. 2015 Apr;141(4):389-97. doi: 10.4103/0971-5916.159250.
Survivin, a member of the inhibitor of apoptosis (IAP) protein family that inhibits caspases and blocks cell death, is highly expressed in most cancers and is associated with a poor clinical outcome. Survivin has consistently been identified by molecular profiling analysis to be associated with high tumour grade cancers, different disease survival and recurrence. Polymorphisms in the survivin gene are emerging as powerful tools to study the biology of the disease and have the potential to be used in disease prognosis and diagnosis. The survivin gene polymorphisms have also been reported to influence tumour aggressiveness as well as survival of cancer patients. The differential expression of survivin in cancer cells compared to normal tissues and its role as a nodal protein in a number of cellular pathways make it a high target for different therapeutics. This review discusses the complex circuitry of survivin in human cancers and gene variants of survivin, and highlights novel therapy that targets this important protein.
生存素是凋亡抑制蛋白（IAP）家族的成员，可抑制半胱天冬酶并阻止细胞死亡，在大多数癌症中高度表达，且与不良临床预后相关。通过分子谱分析一直发现生存素与高肿瘤分级癌症、不同的疾病生存率和复发有关。生存素基因多态性正成为研究该疾病生物学的有力工具，并有可能用于疾病的预后和诊断。据报道，生存素基因多态性也会影响肿瘤侵袭性以及癌症患者的生存率。与正常组织相比，生存素在癌细胞中的差异表达及其在多种细胞途径中作为节点蛋白的作用，使其成为不同治疗方法的高靶点。本综述讨论了生存素在人类癌症中的复杂调控机制及其基因变异，并重点介绍了针对这一重要蛋白的新型疗法。
